-
1
-
-
71449120841
-
-
Crestor (rosuvastatin calcium) prescribing information. Wilmington, DE; August
-
AstraZeneca Pharmaceuticals LP. Crestor (rosuvastatin calcium) prescribing information. Wilmington, DE; August 2003.
-
(2003)
AstraZeneca Pharmaceuticals LP
-
-
-
2
-
-
0030917189
-
Automated peritoneal dialysis: Newimplications for pharmacists
-
Brophy D, Mueller B. Automated peritoneal dialysis: Newimplications for pharmacists. Ann Pharmacother. 1997; 31: 756-764.
-
(1997)
Ann Pharmacother
, vol.31
, pp. 756-764
-
-
Brophy, D.1
Mueller, B.2
-
3
-
-
3042570661
-
Statins in hypercholesterolemia: Adose-specific meta-analysis of lipid changes in randomized double blind trials
-
Edwards JE, Moore RA. Statins in hypercholesterolemia: Adose-specific meta-analysis of lipid changes in randomized double blind trials. BMC Family Practice. 2003; 4: 18-37.
-
(2003)
BMC Family Practice
, vol.4
, pp. 18-37
-
-
Edwards, J.E.1
Moore, R.A.2
-
4
-
-
34748828589
-
Effects of rosuvastatin on outcomes in chronic hemodialysis patients : Baseline data from the AURORA Study
-
Fellström BC, Holdaas H, Jardine AG, Rose H, Schmieder R, Zannad F. Effects of rosuvastatin on outcomes in chronic hemodialysis patients : Baseline data from the AURORA Study. Kidney Blood Press Res. 2007; 30: 314-322.
-
(2007)
Kidney Blood Press Res
, vol.30
, pp. 314-322
-
-
Fellström, B.C.1
Holdaas, H.2
Jardine, A.G.3
Rose, H.4
Schmieder, R.5
Zannad, F.6
-
5
-
-
63849163945
-
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis
-
Fellström BC, Jardine AG, Schmieder RE, Holdaas H et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360: 1395-1407.
-
(2009)
N Engl J Med
, vol.360
, pp. 1395-1407
-
-
Fellström, B.C.1
Jardine, A.G.2
Schmieder, R.E.3
Holdaas, H.4
-
6
-
-
0037024131
-
Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection
-
Hull CK, Penman AD, Smith CK, Martin PD. Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2002; 772: 219-228.
-
(2002)
J Chromatogr B Analyt Technol Biomed Life Sci
, vol.772
, pp. 219-228
-
-
Hull, C.K.1
Penman, A.D.2
Smith, C.K.3
Martin, P.D.4
-
7
-
-
0038645309
-
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (Stellar Trial)
-
Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JM. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (Stellar Trial). Am J Cardiol. 2003; 92: 152-160.
-
(2003)
Am J Cardiol
, vol.92
, pp. 152-160
-
-
Jones, P.H.1
Davidson, M.H.2
Stein, E.A.3
Bays, H.E.4
McKenney, J.M.5
Miller, E.6
Cain, V.A.7
Blasetto, J.M.8
-
8
-
-
0028790320
-
Factors influencing serum levels and peritoneal clearances of low molecular weight proteins in continuous ambulatory peritoneal dialysis
-
Kabanda A, Goffin E, Bernard A et al. Factors influencing serum levels and peritoneal clearances of low molecular weight proteins in continuous ambulatory peritoneal dialysis. Kidney Int. 1995; 48: 1946-1952.
-
(1995)
Kidney Int
, vol.48
, pp. 1946-1952
-
-
Kabanda, A.1
Goffin, E.2
Bernard, A.3
-
9
-
-
1442316135
-
K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease
-
Kidney Disease Outcomes Quality Initiative (K/DOQI) Group
-
Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kid Dis. 2003; 41(Suppl 3): 1-91.
-
(2003)
Am J Kid Dis
, vol.41
, Issue.SUPPL. 3
, pp. 1-91
-
-
-
10
-
-
0037408130
-
Prevention of dyslipidemic risk factors in hemodialysis and CAPD patients
-
Kronenberg F, Lingenhel A, Neyer U, Lhotta K, König P, Auinger M, Wiesholzer M, Andersson H, Dieplinger H. Prevention of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int. 2003; 63 (Suppl 84): 113-116.
-
(2003)
Kidney Int
, vol.63
, Issue.SUPPL. 84
, pp. 113-116
-
-
Kronenberg, F.1
Lingenhel, A.2
Neyer, U.3
Lhotta, K.4
König, P.5
Auinger, M.6
Wiesholzer, M.7
Andersson, H.8
Dieplinger, H.9
-
11
-
-
0344664550
-
Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers
-
Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 2003a; 25: 2822-2835
-
(2003)
Clin Ther
, vol.25
, pp. 2822-2835
-
-
Martin, P.D.1
Warwick, M.J.2
Dane, A.L.3
Hill, S.J.4
Giles, P.B.5
Phillips, P.J.6
Lenz, E.7
-
12
-
-
0041384516
-
A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers
-
Martin PD, Warwick MJ, Dane Al, Cantarini MV. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther. 2003b; 25: 2215-2224.
-
(2003)
Clin Ther
, vol.25
, pp. 2215-2224
-
-
Martin, P.D.1
Warwick, M.J.2
Dane, A.3
Cantarini, M.V.4
-
13
-
-
33846863146
-
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
-
Nichols SJ, Tuzcu E, Sipahi I. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007; 297: 499-508.
-
(2007)
JAMA
, vol.297
, pp. 499-508
-
-
Nichols, S.J.1
Tuzcu, E.2
Sipahi, I.3
-
14
-
-
0001822934
-
Epidemiology of cardiac disease in dialysis patients: Uremia-related risk factors
-
Sarnak MJ, Levy MS. "Epidemiology of cardiac disease" in dialysis patients: Uremia-related risk factors. Sem Dialysis. 1999; 12: 69-76.
-
(1999)
Sem Dialysis
, vol.12
, pp. 69-76
-
-
Sarnak, M.J.1
MS, L.2
-
15
-
-
0037300357
-
Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment
-
Simonson SG, Martin PD, Mitchell P, Schneck DW, Lasseter KC, Warwick MJ. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharm. 2003; 58: 669-675.
-
(2003)
Eur J Clin Pharm
, vol.58
, pp. 669-675
-
-
Simonson, S.G.1
Martin, P.D.2
Mitchell, P.3
Schneck, D.W.4
Lasseter, K.C.5
Warwick, M.J.6
-
16
-
-
71449113162
-
-
U.S. Renal Data System. USRDS 2005 Annual Data Report, Bethesda, MD, The National Institute of Health, National Institute of Diabetes and Digestive Diseases, 2005.
-
U.S. Renal Data System. USRDS 2005 Annual Data Report, Bethesda, MD, The National Institute of Health, National Institute of Diabetes and Digestive Diseases, 2005.
-
-
-
|